Skip to main content


06-05-2023 | Prediabetes | News

Caloric restriction outperforms liraglutide for weight loss in prediabetes

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

11-17-2022 | Cancer | News

Sex differences in diabetes-linked kidney cancer risk

Diabetes has a stronger association with the risk for kidney cancer in women than men, despite men being overall more likely to develop the malignancy, shows a nationwide cohort study from Korea.

11-11-2022 | Prediabetes | News

Ethnicity, deprivation increase risk for prediabetes progression

People with a South Asian or mixed ethnic background and those with social deprivation have a particularly high risk for progressing from prediabetes to type 2 diabetes, research shows.

07-15-2022 | Dementia | News

Progressing prediabetes a ‘key turning point’ for white matter damage

Researchers have identified localized white matter microstructural damage in people with prediabetes and widespread abnormalities in those with type 2 diabetes.

07-12-2022 | Physical activity | News

10,000 steps per day optimal in diabetes or prediabetes

Even small increases in the number of steps taken in a day is associated with a reduced risk for mortality in people with prediabetes or diabetes, say researchers.

07-07-2022 | Risk factors | News

Smoking ‘important risk factor’ for albuminuria in people with prediabetes

Smoking is associated with an increased risk for albuminuria in both people with prediabetes and those with diabetes, but quitting may not immediately circumvent this risk, researchers report.

06-01-2022 | Cardiovascular outcomes | News

No long-term CV benefits seen 2 decades after DPP interventions

People with impaired glucose tolerance who received metformin or intensive lifestyle intervention during the DPP trial show no sign of a significantly reduced cardiovascular disease risk 21 years later, reveal the latest DPPOS results.